Clinical trials: Exercise Metabolism
Renal Transplantion, Kidney Transplantion
A Pilot Trial to Evaluate the Effect of Diet and Exercise in Renal Transplant Recipients on Tacrolimus
The purpose of this trial is to investigate whether a combined dietary and exercise intervention, added to standard care, reduces the expected frequency of insulin resistance in renal (kidney) transplant recipients on tacrolimus.
- Trial name
- PRIDE (NCT00492661)
- Testing
- Tacrolimus With Diet and Exercise Intervention
- Where
- 4 sites in Australia
- Volunteers
- 55 people
- Sponsor
- Janssen-Cilag Pty Ltd
Type 2 Diabetes Mellitus
Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes
The purpose of this study is determine if Metformin XR monotherapy in subjects with type 2 diabetes is non-inferior to Metformin IR monotherapy
- Trial name
- NCT01864174
- Testing
- Metformin XR, Metformin IR
- Where
- 156 sites in United States, Canada and 8 more
- Volunteers
- 1,736 people
- Sponsor
- Bristol-Myers Squibb
Diabetes, Diabetes Mellitus, Type 1
Effect of Exercise on the Absorption of Inhaled Human Insulin in Subjects With Type 1 Diabetes
The trial is conducted in Europe. This clinical pharmacology trial investigates the effect of exercise on the pharmacokinetics and pharmacodynamics of inhaled insulin in subjects with type 1 diabetes.
- Trial name
- NCT00419718
- Testing
- inhaled human insulin
- Where
- Austria
- Volunteers
- 23 people
- Sponsor
- Novo Nordisk A/S
Heart Failure, Congestive
A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
This exploratory proof of concept study will be conducted in patients with stable New York Heart Association (NYHA) Class II-III heart failure.
- Trial name
- NCT01357850
- Testing
- GSK716155
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 82 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Diabetic Neuropathies
Smart Insoles for Improving Sensation, Balance and Mobility in People With Diabetic Peripheral Neuropathy.
The long-term effects of vibrating insoles on improving gait, balance and peripheral sensation in people with diabetic peripheral neuropathy remain unknown.
- Conditions
- Diabetes Mellitus, Diabetic Neuropathies, Unsteadiness
- Trial name
- Pathfeel (NCT06855420)
- Testing
- Vibration on, Vibration off
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Walk With Path
Hypercholesterolemia, Atherosclerosis
Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)
The primary objective is to evaluate the efficacy and safety of coadministration of ezetimibe 10 mg with atorvastatin 10 mg in untreated subjects with primary hypercholesterolemia and coronary heart disease for whom diet and…
- Conditions
- Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease
- Trial name
- NCT00650689
- Testing
- Ezetimibe + Atorvastatin, Atorvastatin
- Volunteers
- 122 people
- Sponsor
- Organon and Co
Diabetes Mellitus Type 2
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
This 3 arm study will assess the efficacy, safety and tolerability of taspoglutide compared to placebo in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
- Trial name
- NCT00744926
- Testing
- taspoglutide
- Where
- 58 sites in United States, Australia and 9 more
- Volunteers
- 373 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone.
- Trial name
- ACHIEVE-1 (NCT05971940)
- Testing
- Orforglipron
- Where
- 89 sites in United States, China and 4 more
- Volunteers
- 559 people
- Sponsor
- Eli Lilly and Company
Iron Deficiency, Chronic Heart Failure
Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure
The purpose of this study is to confirm that treatment with IV ferric carboxymaltose improves exercise capacity, physical functioning and quality of life in patients with iron deficiency and chronic heart failure.
- Trial name
- EFFECT-HF (NCT01394562)
- Testing
- Ferinject (ferric carboxymaltose), Standard of Care
- Where
- Netherlands
- Volunteers
- 174 people
- Sponsor
- Vifor Pharma
Type 2 Diabetes
Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone
This protocol will compare 24 hour glucose control for subject taking saxagliptin and metformin extended release (XR) versus metformin XR alone
- Trial name
- NCT00683657
- Testing
- Saxagliptin
- Where
- 27 sites in United States, Argentina and 6 more
- Volunteers
- 93 people
- Sponsor
- AstraZeneca
PreDiabetes, Older Adult
Examining the Effects of Vivo on Physical Function and Glycemic Level in Sedentary Older With Prediabetes.
This is a 12-week randomized, controlled trial that seeks to examine the effect of Vivo on 1) change in lower extremity strength defined as number of chair stands done in 30 seconds and 2) change in average glycemic level (HbA1c)…
- Conditions
- PreDiabetes, Older Adult, Muscle Loss, Muscle Weakness
- Trial name
- NCT06458530
- Testing
- Vivo
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Impactiv, Inc.
Type 2 Diabetes Mellitus
Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)
This is a study to assess the safety and efficacy of the addition of ipragliflozin to sitagliptin in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on sitagliptin, diet, and…
- Trial name
- NCT02564211
- Testing
- Ipragliflozin, Sitagliptin
- Volunteers
- 77 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Placebo-Controlled Clinical Nutrition Study of the Metabolic Effects of Food Product WBF-0011 in Type 2 Diabetes
This 12 week placebo-controlled study evaluates the safety and impact of 2 different strengths of the medical food formulation WBF-0011.
- Trial name
- NCT04047537
- Testing
- Medical Food Formulation 1, Medical Food Formulation 2
- Where
- Ireland
- Volunteers
- 41 people
- Sponsor
- Pendulum Therapeutics
Glucose Intolerance
Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)
This study is being done to evaluate the safety, efficacy, and dose level of sitagliptin (MK-0431/ONO-5435) used once daily (qd) in Japanese participants with impaired glucose tolerance who have inadequate glycemic control using…
- Trial name
- NCT01405911
- Testing
- Sitagliptin 25 mg, Sitagliptin 50 mg
- Volunteers
- 242 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity and Type 2 Diabetes
BMS-646256 in Obese and Overweight Type 2 Diabetics
This is a placebo-controlled, randomized, double-blind, parallel arm, multicenter, dose-ranging phase IIb trial to assess glycemic and weight loss efficacy and safety of BMS-646256 in overweight and obese patients with type 2…
- Trial name
- NCT00541567
- Testing
- ibipinabant
- Volunteers
- 600 people
- Sponsor
- Solvay Pharmaceuticals
Primary Mitochondrial Disease
Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
The primary objective of the FALCON study is to evaluate the efficacy of KL1333 on selected disease manifestations of primary mitochondrial disease (PMD) following 48 weeks of treatment.
- Trial name
- FALCON (NCT05650229)
- Testing
- KL1333
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 180 people
- Sponsor
- Pharming Technologies B.V.
Type 2 Diabetes
Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone
This study intends to compare the efficacy and safety of dapagliflozin versus placebo in treatment-naïve subjects with type 2 diabetes who have inadequate glycaemic control with diet and exercise alone.
- Trial name
- NCT01257412
- Testing
- Dapagliflozin
- Where
- 15 sites in India
- Volunteers
- 375 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)
This trial will evaluate the efficacy and safety of ertugliflozin monotherapy in the treatment of participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on diet and exercise.
- Trial name
- NCT01958671
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 10 mg, Metformin
- Volunteers
- 461 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
This study is conducted to determine the most appropriate therapeutic doses of BI 10773 in Japanese patients with T2DM at first treatment period.
- Trial name
- NCT01193218
- Testing
- BI 10773
- Where
- 32 sites in Japan
- Volunteers
- 547 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)
This study will evaluate whether the addition of sitagliptin reduces hemoglobin A1C (A1C) more than the addition of placebo for participants with type 2 diabetes mellitus (T2DM) on a steady dose of acarbose.
- Trial name
- NCT01177384
- Testing
- Sitagliptin phosphate, Acarbose, Glimepiride
- Volunteers
- 380 people
- Sponsor
- Merck Sharp & Dohme LLC